Alphatec Holdings, Inc.

Alphatec Holdings, Inc.(ATEC)股票分析

$9.440

-0.128 (-1.36%)收盘时

Loading chart…
High
9.650
Open
9.550
VWAP
9.50
Vol
1.21M
Mkt Cap
1.45B
Low
9.400
Amount
11.48M
EV/EBITDA, TTM
25.16

Alphatec Holdings, Inc., through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A.S. and SafeOp Surgical, Inc., is a medical device company. It is focused on the design, development, and advancement of technology for better surgical treatment of spine disorders. Its Organic Innovation Machine is focused on developing new approaches that integrate with its expanding InformatiX Platform to better inform surgery and safely and reproducibly achieve the goals of spine surgery. Its technologies include InformatiX, positioners, access systems, implants and fixation systems, and biologics. Its InformatiX product platform comprises EOS imaging system, EOS Insight alignment assessment and surgical planning web/mobile platform, SafeOp Neural InformatiX System and navigation-enabled robotics platform. It has developed approach-specific patient positioning systems that integrate with its other access systems, providing for a more rigid construct and enhanced reproducibility.

atecspine.com

AI analysis of Alphatec Holdings, Inc. (ATEC)

buy

Alphatec Holdings Inc is a good buy right now due to its recent revenue growth of 17% year-over-year in Q2 2026, reaching $214 million, and a gross margin improvement to 70.34%. The stock is currently priced at $9.44, significantly below the analyst price target of $15, indicating a potential upside of approximately 58%. However, investors should be cautious of the high forward P/E ratio of 384.62, which suggests that the stock may be overvalued if growth does not continue as expected.

Analyst Ratings (3)

+157.73% upside
Buy
2 Buy
1 Hold
0 Sell
Current: 9.44
最低
20.00
平均
24.33
最高
28.00

BMO Capital

2026-08-05

目标价

$12

Outperform

UBS

2026-07-28

目标价

$15

Buy

Stephens

2026-07-23

目标价

$15

Overweight

Stifel

2026-07-08

目标价

$13

Buy

Barclays

2026-05-07

目标价

$24

Overweight

估值指标

The current forward P/E ratio for Alphatec Holdings, Inc. (ATEC) is 384.62, compared to its 5-year average forward P/E of 14.23.

Forward P/E

Strongly Overvalued
5Y Average P/E
14.23
Current P/E
384.62
高估
104.98
低估
-76.52

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
68.17
Current EV/EBITDA
25.16
高估
253.35
低估
-117.00

Forward P/S

Undervalued
5Y Average P/S
2.68
Current P/S
1.43
高估
3.57
低估
1.79

Alphio AI Price Scenarios for ATEC

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%ATEC

$14.87

情景价格

B

Base

Base · 50%ATEC

$14.86

情景价格

B

Bear

Bear · 25%ATEC

$14.36

情景价格

Whales holding ATEC

T

Tremblant Capital Group

+ HoldingATEC

+6.35%

3M Return

T

Tremblant Advisors LP

+ HoldingATEC

+2.37%

3M Return

P

Paradigm Capital Management, Inc.

+ HoldingATEC

-14.65%

3M Return

事件时间线

2026-08-04 (ET)

17:00:00

ATEC Reports Q2 Revenue of $214M, Exceeds Expectations

17:00:00

Company Reaffirms FY2026 Revenue Outlook, Raises EBITDA Guidance to $140 Million

2026-05-05 (ET)

16:50:00

ATEC Reports Q1 Revenue of $192.1M, Below Expectations

16:50:00

Company Expects Total Revenue of $882 Million for Fiscal Year 2026

资讯

ATEC FAQ — answered by Alphio AI

Alphatec Holdings, Inc., through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A.S. and SafeOp Surgical, Inc., is a medical device company. It is focused on the design, development, and advancement of technology for better surgical treatment of spine disorders. Its Organic Innovation Machine is focused on developing new approaches that integrate with its expanding InformatiX Platform to better inform surgery and safely and reproducibly achieve the goals of spine surgery. Its technologies include InformatiX, positioners, access systems, implants and fixation systems, and biologics. Its InformatiX product platform comprises EOS imaging system, EOS Insight alignment assessment and surgical planning web/mobile platform, SafeOp Neural InformatiX System and navigation-enabled robotics platform. It has developed approach-specific patient positioning systems that integrate with its other access systems, providing for a more rigid construct and enhanced reproducibility. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Alphatec Holdings Inc is a good buy right now due to its recent revenue growth of 17% year-over-year in Q2 2026, reaching $214 million, and a gross margin improvement to 70.34%. The stock is currently priced at $9.44, significantly below the analyst price target of $15, indicating a potential upside of approximately 58%. However, investors should be cautious of the high forward P/E ratio of 384.62, which suggests that the stock may be overvalued if growth does not continue as expected.

3 analysts cover ATEC: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 24.33.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始